Top 20 BioPharma Companies based on 2020 Total Revenue
- Despite having the global Covid-19 pandemic- the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally
- All of the Biopharma companies on our list are on the front line to combat this global crisis. The top 20 companies on the list changed from their 2019 ranking- leading to major ups & downs in the positions
- J&J remains at the top with a revenue of $82.5B- followed by Roche & Bayer with $65.95B & $50.62B respectively. PharmaShots has compiled a list of the top 20 biopharma companies based on their 2020 total revenue
Total Revenue: $13.44B
Pharma Segment Revenue: $13.44B
Founded Year: 1978
Market Cap: $268.02B
Total Employees: ~ 9,100
Non-Pharma Segment Revenue: Nil
Headquarters: Massachusetts-United States
Stock Exchange: NASDAQ
Biogen is a global biopharmaceutical company focused on discovering- developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. In Mar 2020- Biogen acquired BIIB118 (CK1 inhibitor) from Pfizer- while in Oct 2020 collaborated with Denali to co-develop & co-commercialize Denali's LRRK2 inhibitors for PD.
Total Revenue: $16.65B
Pharma Segment Revenue: $16.65B
Founded Year: 1944
Market Cap: $11.34B
Total Employees: ~40,216
Non-Pharma Segment Revenue: Nil
Headquarters: Petah Tikva- Israel
Stock Exchange: NYSE
Teva is a global pharmaceutical company that deals with generics- specialty- and over-the-counter products. In Jan 2020 and Mar 2020- the company launched Herzuma (trastuzumab-pkrb) a trastuzumab biosimilar- in Canada and the US- respectively.
Total Revenue: $20.86B
Pharma Segment Revenue: $20.86B
Founded Year: 1989
Market Cap: $69.25B
Total Employees: ~45,323
Non-Pharma Segment Revenue: Nil
Headquarters: Bagsvaerd- Denmark
Stock Exchange: Copenhagen
Novo Nordisk is a global healthcare company- and a leader in diabetes and obesity care. It has a strong presence in other chronic diseases such as NASH- CV- and AD. In 2020- Novo Nordisk's Rybelsus got approved in the EU- the UK- and Japan.
Total Revenue: $21.44B
Pharma Segment Revenue: $8.11B
Founded Year: 1800
Market Cap: $173.48B
Total Employees: ~$58,000
Non-Pharma Segment Revenue: $13.33B
Headquarters: Darmstadt- Germany
Stock Exchange: ETR
The Merck Group- commonly known as Merck KGaA- is a German multinational science and technology company and its focus includes oncology- immuno-oncology- and neurology & immunology. In June 2019- the US FDA has approved IND for M5049 to treat Covid-19 pneumonia.
Total Revenue: $23.92 B
Pharma Segment Revenue: $17.62B
Founded Year: 1885
Market Cap: Nil
Total Employees: ~ 52,000
Non-Pharma Segment Revenue: $6.3B
Headquarter: Ingelheim am Rhein- Germany
Stock Exchange: Nil
Boehringer Ingelheim is a research-driven biopharmaceutical company and has three core business areas: Human Pharma- Animal Health- and Biopharmaceutical Contract Manufacturing. Boehringer Ingelheim reinforced its position in immune-oncology therapies by acquiring shares in Northern Biologics- which was subsequently renamed BI IO Canada.
Total Revenue: $24.53B
Pharma Segment Revenue: $24.53B
Founded Year: 1901
Market Cap: $182.32B
Total Employees: ~34,960
Non-Pharma Segment Revenue: Nil
Headquarters: Indiana- United States
Stock Exchange: NYSE
Eli Lilly is an American pharmaceutical company headquartered in Indianapolis- Indiana. The company develops- manufactures- and markets products in one business segment i.e human pharmaceutical products. In 2020- Baricitinib was granted EUA for suspected or laboratory-confirmed COVID-19- in combination with remdesivir- in hospitalized adults and pediatric patients.
Total Revenue: $24.69B
Pharma Segment Revenue: $24.69B
Founded Year: 1987
Market Cap: $65.60B
Total Employees: ~ 13,600
Non-Pharma Segment Revenue: Nil
Headquarters: California- United States
Stock Exchange: NASDAQ
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery- development- and commercialization of innovative medicines. In 2020- Gilead entered 18 partnerships and acquisitions to enhance its commercial portfolio and clinical pipeline across multiple therapeutic areas which include the acquisition of Immunomedics that adding Trodelvy and other pipeline programs to our oncology portfolio.
Total Revenue: $25.40B
Pharma Segment Revenue:$25.40B
Founded Year: 1980
Market Cap: $248.12B
Total Employees: ~ 22,000
Non-Pharma Segment Revenue: Nil
Headquarters: California- United States
Stock Exchange: NASDAQ
Amgen is an American multinational biopharmaceutical company headquartered in Thousand Oaks- California. In Dec 2020- the US FDA has approved d Riabni- a biosimilar to Rituxan (rituximab)- for adult patients with NHL- CLL- granulomatosis with polyangiitis- and microscopic polyangiitis and was launched in the US in Jan 2021.
Total Revenue: $26.60B
Pharma Segment Revenue: $26.60B
Founded Year: 1999
Market Cap: $131.78B
Total Employees: ~76,100
Non-Pharma Segment Revenue: Nil
Headquarters: Cambridge- United Kingdom
Stock Exchange: NYSE
AstraZeneca is a global pharmaceutical focusing on Oncology; Cardiovascular- Renal & Metabolism and Respiratory & Immunology. In May 2020- AZ collaborated with RedX and got an exclusive global license to develop & commercialize RXC006 targeting fibrotic diseases including IPF.
Total Revenue: $34.60B
Pharma Segment Revenue: $4.30B
Founded Year: 1900
Market Cap: $120.11B
Total Employees: ~109,000
Non-Pharma Segment Revenue: $30.3B
Headquarters: Illinois- United States
Stock Exchange: NYSE
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Illinois. It has four segments: Established Pharmaceutical Products- Diagnostic Products- Nutritional Products- and Medical Devices. The products in the pharmaceutical segment include Creon- Duphaston- Lipanthyl- TriCor- Serc- etc.
Total Revenue: $41.90B
Pharma Segment Revenue: $41.90B
Founded Year: 1849
Market Cap: $35.91B
Total Employees: ~ 1,01,200
Non-Pharma Segment Revenue: Nil
Headquarters: New York- United States
Stock Exchange: NYSE
Pfizer Inc. is a research-based- global biopharmaceutical company. In Apr 2020- it collaborated with BioNTech to develop- manufacture- and commercialize an mRNA-based coronavirus vaccine program- BNT162- aimed at preventing COVID-19. While in Nov 2020- it spun off Upjohn Business with Mylan- which created a new global generic pharmaceutical company- Viatris.
Total Revenue: $42.51B
Pharma Segment Revenue: $42.51B
Founded Year: 1887
Market Cap: $62.06B
Total Employees: ~30,250
Non-Pharma Segment Revenue: Nil
Headquarters: New York- United States
Stock Exchange: NYSE
Bristol-Myers Squibb (BMS) is an American pharmaceutical company focused on oncology- cardiovascular- and immunology. In Oct 2020- BMS obtained a global exclusive license to Dragonfly's IL-12 investigational immunotherapy program- including its extended half-life cytokine DF6002. Later it has completed the acquisition of MyoKardia & Forbius in Nov & Sep 2020 respectively.
Total Revenue: $44.07B
Pharma Revenue: $30.19B
Founded Year: 1973
Market Cap: $100.34B
Total Employees: ~ 99,412
Non-Pharma Segment Revenue: $13.88B
Headquarter: Paris- France
Stock Exchange: EPA
Sanofi is a global healthcare leader in vaccines providing healthcare solutions in 170+ countries around the world. In 2020- Sanofi entered into multiple agreements which include its collaboration with Kiadis Pharma- Kymera Therapeutics- Principia Biopharma and has completed the acquisition of Synthorx for $68/ share in cash- representing an aggregate equity value of ~$2.5B.
Total Revenue: $45.80B
Pharma Segment Revenue: $45.80B
Founded Year: 2012
Market Cap: $105.21B
Total Employees: ~47,000
Non-Pharma Segment Revenue: Nil
Headquarters: Illinois- United States
Stock Exchange: NYSE
AbbVie is a global- research-based biopharmaceutical company that develops therapies majorly for chronic autoimmune diseases- oncology- virology with additional targets like cystic fibrosis and women's health and has an enriched pipeline in immunology and neuroscience. The company completed Allergan's acquisition which enhances its growth platform.
Total Revenue: $46.59B
Pharma Segment Revenue: $30.84B
Founded Year: 2000
Market Cap: $90.76B
Total Employees: ~ 94,066
Non-Pharma Segment Revenue: $15.75B
Headquarter: Brentford- United Kingdom
Stock Exchange: LON
GSK is a global healthcare company serving the world with drugs- vaccines & consumer healthcare products and is a leader in the areas of respiratory and HIV. In 2020- GSK collaborated with Sanofi to develop an adjuvanted COVID-19 vaccine and allied with VIR and Innovax to combat COVID-19.
Total Revenue: $47.99B
Pharma Segment Revenue: $43.02B
Founded Year: 1891
Market Cap: $76.12B
Total Employees: 74,000
Non-Pharma Segment Revenue: $4.97B
Headquarters: NewJersey- United States
Stock Exchange: NYSE
Merck & Co. is a global health care company that delivers innovative health solutions through its prescription medicines- vaccines- biological therapies- and animal health products. In Feb 2020- Merck announced its intention to spin off products from its women's health- biosimilars and established brands businesses into a new independent- a publicly-traded company named Organon & Co. (Organon) through the distribution of Organon's publicly traded stock to the company shareholders. The spin-off is expected to be completed late in Q2'21.
Total Revenue: $48.66B
Pharma Segment Revenue: $48.66B
Founded Year: 1996
Market Cap: $86.62B
Total Employees: ~105,794
Non-Pharma Segment Revenue: Nil
Headquarters: Basel- Switzerland
Stock Exchange: SIX Swiss Exchange- NYSE
Novartis is a multinational group of companies specializing in research- development- manufacturing- and marketing with a broad range of healthcare solutions including generic and ophthalmic therapies. In Nov 2020- Novartis has secured a global license to Mesoblast's cell therapy remestemcel-L in the treatment of COVID-19 while its Tabrecta got FDA's approval for NSCLC with METex14 in May'2020.
Total Revenue: $50.62B
Pharma Segment Revenue: $21.08B
Founded Year: 1863
Market Cap: $63.33B
Total Employees: ~99,538
Non-Pharma Segment Revenue: $29.54B
Headquarters: Leverkusen- Germany
Stock Exchange: ETR
Bayer is a leading life science firm with three divisions pharmaceuticals- consumer health- and crop science. In Sept'2020- Bayer completed the acquisition of 100% of the shares in biotech company KaNDy- further expanding its development portfolio in women's health while in Dec'2020- it acquired Asklepios BioPharmaceutical.
Total Revenue: $65.95B
Total Employees: ~98,000
Pharma Segment Revenue: $50.35B
Non-Pharma Segment Revenue: $15.6B
Founded Year: 1896
Headquarters: Basel, Switzerland
Market Cap: $346.12B
Stock Exchange: SIX Swiss Exchange
Roche is a Swiss multinational healthcare company operating worldwide under pharmaceuticals and diagnostics divisions. In 2020, Roche initiated several approaches to fight against COVID-19. In Aug, Roche and Regeneron joined forces to develop, manufacture, and distribute Regeneron’s Ab combination. In October, Roche and Atea collaborated to develop, manufacture, and distribute AT-527 targeting COVID-19 across the globe.
Total Revenue: $82.50B
Total Employees: ~34,500
Pharma Segment Revenue: $45.57B
Non-Pharma Segment Revenue: $36.93B
Founded Year: 1887
Headquarter: New Jersey, United States
Market Cap: $163.61B
Stock Exchange: NYSE
Johnson & Johnson (J&J) is an American multinational healthcare company focused on the development and commercialization of pharmaceutical, medical device, and consumer packaged products. In Sept’2020, J&J begun a P-III study of its COVID-19 vaccines and has received $1B in Federal Vaccine Production Funding. Additionally, J&J acquired Momenta Pharmaceutical for $7.5B in Aug’2020.
Sources: Company annual reports, SEC filings, press releases, and company websites.
Market Cap source: Google finance (as on 8th Apr 2021)
All revenues are reported in USD.
Note: Takeda is not included in the top 20 list, as its actual revenue is not available.
Related Post: Top 20 BioPharma Companies based on 2019 Total Revenue
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com